Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70278 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Min Xiao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Phase 1 Clinical Trial Research Unit, The Sixth People's Hospital of Zhengzhou, Zhengzhou, Henan, People's Republic of China. Hauptthemen laut MEDLINE: Carnosine, Fasting, Organometallic Compounds. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The study aimed to demonstrate bioequivalence between generic and original polaprezinc granules by comparing pharmacokinetic (PK) profiles in healthy Chinese subjects under fasting and fed conditions. This PK investigation was conducted with two independent, randomized, open‐label, single‐dose, two‐period, cross‐over studies. Healthy Chinese fasting ( N = 24, 75 mg) or fed ( N = 24, 300 mg) subjects randomly received a single oral dose of the test or reference polaprezinc granules at each period. Blood samples were collected pre‐ and post‐dose for up to 12 h. Blood zinc was determined using a validated ICP‐MS method. Primary PK endpoints were calculated using non‐compartmental methods, including peak concentration ( C max ) and the areas under the plasma concentration‐time curve (AUC 0–t , AUC 0–∞ ). The geometric mean ratios (GMR) in primary PK endpoints between the test and reference products with 90% confidence intervals (CI) were calculated. Treatment‐emergent adverse events were assessed. In the fasting study, C max , AUC 0–t and AUC 0–∞ were 1.30 ± 0.30 μg/mL, 4.06 ± 1.13 h·μg/mL, and 4.43 ± 1.04 h·μg/mL following 75 mg test product. In the fed study, C max , AUC 0–t and AUC 0–∞ were 0.91 ± 0.26 μg/mL, 3.26 ± 1.06 h·μg/mL, and 3.37 ± 1.07 h·μg/mL following 300 mg test product. The reference product had comparable PK profiles. All 90% CIs of GMRs in C max , AUC 0–t and AUC 0–∞ between the two products were within 80.0%–125.0%. Both study products were well‐tolerated with no serious adverse events. The generic and original polaprezinc granules were bioequivalent by pharmacokinetic comparisons in healthy Chinese subjects under fasting and fed conditions. The two polaprezinc formulations were well‐tolerated with no new safety signals. Trial Registration: CTR20210011
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase 1 Clinical Trial Research Unit, The Sixth People's Hospital of Zhengzhou, Zhengzhou, Henan, People's Republic of China.
- Department of Pharmacy, Huai'an Chuzhou Hospital of Traditional Chinese Medicine, Huai'an, Jiangsu, People's Republic of China.
- Department of Clinical Medicine, Haisco Pharmaceutical Group co., Ltd., Chengdu, Sichuan, People's Republic of China.
ORCID-Profile: Min Xiao, Tian Dou, Jia Ji, Caihua Zhu, Yuan Yuan, Hongmin Zhou, Fangqiong Li, Guang Li, Shuang Li
Zitieren
APA
Xiao, M., Dou, T., Ji, J., Zhu, C., Yuan, Y., Zhou, H., Li, F., Li, G., & Li, S. (2025). Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Clinical and Translational Science. https://doi.org/10.1111/cts.70278
Vancouver
Xiao M, Dou T, Ji J, Zhu C, Yuan Y, Zhou H, et al. Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Clinical and Translational Science. 2025. doi:10.1111/cts.70278
BibTeX
@article{Xiao2025,
author = {Xiao, Min and Dou, Tian and Ji, Jia and Zhu, Caihua and Yuan, Yuan and Zhou, Hongmin and Li, Fangqiong and Li, Guang and Li, Shuang},
title = {Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70278}
}
EUVIMED